The Phase 2b BROADEN2 study, which focuses on moderate-to-severe atopic dermatitis, now aims to deliver topline results by the end of 2026 rather than the previously anticipated mid-2027 window. Following these results, Kymera plans to initiate Phase 3 trials by mid-2027, pending discussions with regulators. During today's session, the stock reached a 52-week peak of $130.05.

Chief Executive Nello Mainolfi attributed the rapid enrollment to significant demand from patients and providers seeking an oral alternative to existing therapies. The global study involves 200 adult and adolescent participants, measuring success through the percentage change in Eczema Area and Severity Index scores over 16 weeks. Beyond dermatology, the company continues to test KT-621 for asthma, with those trial results projected for late 2027.